ML20214D979
Jump to navigation
Jump to search
| ML20214D979 | |
| Person / Time | |
|---|---|
| Site: | 03019521 |
| Issue date: | 01/28/1987 |
| From: | Riedlinger B NRC OFFICE OF INSPECTION & ENFORCEMENT (IE REGION V) |
| To: | |
| Shared Package | |
| ML20214D981 | List: |
| References | |
| 50-19913-01, 50-19913-1, NUDOCS 8705210582 | |
| Download: ML20214D979 (4) | |
See also: IR 05000199/2013001
Text
{{#Wiki_filter:twwwjww_mememumumm&4_&pummmmmm,memmppummmmmmmmmmmmmmmmmmmmq
dicr 370
PAGE
1
OF
4 PAGES
;
(3 83) U.S. NUCLE AR QEGULATOQY COMMISSION
MATERIALS LICENSE Amendment No. 11 I
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 -438), and Title 10,
Code of Federal Regulations, Chapter 1, Parts 30,31,32,33,34,35,40 and 70, and in reliance on statements and representations g
f
heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct. l
source, and special nuclear material designated below; to use such material for the purpose (s) and at the place (s) designated below; to t
deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This {I
license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is I
subject to all applicable rules, regulations and orders of the Nudear Regulatory Commission now or hereafter in effect and to any
I
conditions specified below.
Licenwe !
I
In accordance with application ,1
dated December 17, 1986 i
l
l- Ketchikan General Hospital 3. License number 50-19913-01 is amended in
its entirety to read as follows:lj
{
i
2. 3100 Tongass Avenue .r . ,cs I
'
Ketchikan, Alaska 99901 g 4. Expirationdate January 31, 1992 I
>
5. Docket or
li '
[
Reference No. 3d-19521
6. Ilyproduct, source, and/or ,
7. Chemical and/or physleal 8. Maximum amount that licensee i
l
special nuclear material form ;may possess at any one time lL
( -
F
under this license
f
A. Any byproduct material A. 'Any radiopharmaceutical A. -As necessary for uses I
listed in Groups I and listed in Groups I and II authorized in L
!! of Schedule A, , of Schedule A. Section ( Subitem 9.A.
~
j
Section 35.100 of ,
35.100 of 10 CFR 35 L
10 CFR 35 ', '
I
,3 .
s .
I
B. Any byproduct material B.. . Any forni listed ;in Group III B. '2 curies of each (
listed in Group 111 , - of Schedule A', Section 35.100 . byproduct material t
of Schedule A, '; '~
of 10 CFR 35.
~
~' - J ~
J authorized in l
Section 35.100 of ' *
Subitem 6.0. 10 t
' t ' I
CFR 35 '
>
! I
'
C. Any byproduct material 10.. Any 'C. 3 millicuries of each l
listed in Section 31.11(a) , byproduct material t
of 10 CFR 31 , authorized in ;L
Subitem 6.F. t
I
t
!E
I
'l
I
'L
lll
L
i
i
I
L
L
i
kI
8705210502 870120 !L
HE05 LIC30 PDR ll
50-19913-01 1 .
lrl
u...................................................;....a
I l
$L(01
L----b-------------------------------------------------y
C Form 374A U.S. NUCLEAR cEGULATORY COMMISSION ,,oe 2 y 4 ,,oes l
Licen,e number I
50-19913-01
MATERIAL.S LICENSE ** "*"**""" l
SUPPLEMENTARY SHEET
030-19521 l
;
I
Amendment No. 11 l
l
l
6. BYPRODUCT, SOURCE, AND/0R I
7. CHEMICAL AND/0R PHYSICAL 8. MAXIMUM AMOUNT THAT LICENSEE
SPECIAL NUCLEAR MATERIAL FORM MAY POSSESS AT ANY ONE TIME l
UNDER THIS LICENSE i
l
D. Xenon-133 D. Gas or gas in solution D. 50 millicuries I
that is the subject of I
an active (i.e., not
l
withdrawn or terminated) i
"NewDrug$pp]jcation" l
(NDA) GpproVed by)FD or
' I
a I
(~ Nq * active (i .e;. , not. / I
s
y2 on " clinical hold")
" Ithdrawn,
Notice of Claimed terminated'or:')/gg
s I
i
'y Investigational Exemption
h for a New Drug" (IND) that 74) ,
i
- I
A I
4[f K?hasbeenacceptedby}#/DA 4,
MVN '
, I
E. Phosphorus 32 /U E.'[Abysolubl6ihosp teY E.O10 millicuries l
4
f that,has ,been[ manufactured,
. labeled.jpackaged',jandle
~
O i
b
j- 23 p
(j) Q('c' ij distr 1b~uted'inaccordance/,
sitha!specificElicense, issued j i
r v o c7 N
Wdl,<;10pursuantCFR (tolSection
s 32l72e f I
O- ' Missuedk'32 'o'rM ' pecific license % 4 I
m
to alnia~nUfscturer by anh
M [4 bAgreBinent(State' pursuant to ,. l
y',/4
equivalent"st' ate regulations M
4(Jjpp */
i
I
F. Americium 241 SFs Sealed sources M, AF. Not to exceed
,/ (AmershamAMC.24) 94 14 millicuries l
per source
[i s 4 , o M,
9. Authorized use >
>
A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100
of Title 10, Code of Federal Regulations. l
>
I
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed p
in Group III of Schedule A, Section 35.100 of Title 10. Code of Federal I
Regulations.
C. In vitro studies. l
l
Blood flow and pulmonary function studies.
'
O. >
>
- E. For treatment of polycythemia vera, leukemia and bone metastases. >
p
F. Anatomical marker,
f
,
>
>
YmundstamamumUnimamumumusumDmiUm&diamusumDminUmumadmQuGEhUnimQsumDaw wm imUinUmGm imimpaGuaris:wYfun=G=nmD
inu n u m $m u m a n m a m m e - z u m - - - - m = = m m m m m m m m m m a - - - m a m m a = = - - - - a n u m ;
l NRC Form 374A U 1 NUCLEAR C8.GULATORY COMMISSION ,,og 3 o, 4 ,,oes l
I
I License number l
l MATERIALS LICENSE !
I SUPPLEMENTARY SHEET I
0 1 21
I l
l l
l Amendment No. 11 p
I I
I l
CONDITIONS
l l
l 10. Licensed material shall be used only at Ketchikan General Hospital, 3100 l l
l Tongass Avenue, Ketchikan, Alaska. I
I I
I
11. Licensed material listed in Item 6 above is authorized for use by, or under the l
l supervision of, the following individual (s) for the materials and uses
indicated: l
l i
I I
Zeke L. Hendricks, M.D. l
h lg* Q $ s'1,j I, and III
I I
I In vitro uitudies l
l Xenon 133 ~ Q, I
i
Phosphorus 32 as, soluble phosphate for l
l
treatment of poly?ythemia vera, i
I %g - leukemia, and bon etastases i
Arthur K. Harris,. 8. 1 I,$$ IIIM-
I
D GroupsI,)'u'diei;
In vitro st I
l /% ":M
j ' CXenon{33ff$ O l
l
-
M:? /gPhosphoruss32Jassoluble+phosphatefor i
I
.* - .
(3$ t' i
b T60k$mlahand bo,ne meta' stases l
't i.% [% reatinent- of polycythemi
l
I
I John C. Jowett, M:D.
fn 'c[rdej N%g70 l Groupsg
gV
y-{y!Y11 da/,jp/,
'nd'III >
O I
I
I
D k,$ }[ 7!I M Vitfo studies' ND I
l h 2v Ei3iiTJ3%y o%C h
E's)M(Q'*pl}~ l
i
I
& QR ,r p
12. The Radiation Protecti6n Officer \fo(the ~de'tivitjesjauthorfzgd by this license
h') ,
i
I
I
is Dr. Zeke L. Hendrfcks; 'C{Jg */
, %)
M i
l
*f/
l 13. For a period not to excee(sixty (60) days in any caliiSar 1 year, a visiting l
l
physician is authorized to use wlicensed njater,ialjfor human use under the terms ,
of this license, provided the visitihg physician:P
'
I l
I i
I A. Has the prior written permission of the hospital's Administrator and its l
Radiation Safety Committee, and
l l
l k
i
B. Is specifically named as a user on a Nuclear Regulatory Commission license i
I authorizing human use, and i
I I
I C. Performs only those procedures which the physician is specifically i
I
authorized to perform pursuant to a license issued by the Nuclear I
l Regulatory Comission. l
l l
l The licensee shall maintain for inspection by tne Commission copies of the p
I written permission specified in A. above and of the license (s) specified in B. p
I and C. above for a period of 5 years from the date permission is granted under i
I A. above. I
I >
I I
I I
I I
bisasmw-----i ri r-----T-,iirr- . ., ,. m ,,,,, 1 . , ,,,,,. . c;7 Tc m 7TT 7 7.,m m 2
-. _ - _ _
-. .
m RC-FormL------------------A------------------------------y
M4A U.S. NUCLEAR REGULAT;TtV COMMISSION l 4 4
p,g g, PAGES I
License number l
~ ~
MATERIALS LICENSE ' " !
SUPPLEMENTARY SHEET
0 019b1 I
I
' I
J . Amendment No.11 1
l
l
CONDITIONS
l
(continued) !
I
14 The licensee is authorized to hold radioactive material with a physical I
half-life of less than 65 days for decay-in-storage before disposal in ordinary I
trash provided: l
A. Radioactive waste to be disposed of in this manner shall be held for decay !
aminimumoften(10)hal 1
9REGg !
8. Prior to disposal as(norrsif' waste, radioactive waste shall be surveyed to I
determinethatitq*radioactivitycannotbedisting'ufshedfrombackground.* l
All radiation labels'shall be rerroved or obliteratedg g
C.
T
Generator columns shall be segregated so that they-may be, monitored
A I
p
I
separatelytk'e'n'sure'decaytobackgroundlevelsip/r.idr to-disposal.
/ TQ M I
15.
The licensee may j, transport licensed in/a.c/$
" matefiil,tionfof) Radioactive' Material".co l
of10CFRPart7(,k,Packaginj;and'fransporta
Oil ( j% d Ihsp
16. Except as specif)cally pr,ovided(oth'efwisTTn tfiisilicense,, the illcensee shall
'#
l
y
conduct its prograq in accordance i
procedures contained in.;theldocuine;withwthenstatements
nts drepresentations, and i
The Nuclear Regulatory Coimils'sfon'Mfelg{nclu'dijigfa6s
* ~
ulations. shall7 govern unless the enclosbresPlisted N
statements,represenkatio'ns)andq@edursQih
,
correspondence are Taore restridive 'tha ?the $the_Jicensee's g# ipplication and!j
Q
'
\\ .,(Jj j' egulations.
hA C" J
9/ \') p
I
A. Application
B. Model ALARA dated
Program De& emberin17,
'c66tained
ofRegulatoryGuideIg!8(Rev.1)
1986;
Append x i,0 M
gb
i
l
# 4 p ,d , <,r Rr'
M. 4
.
,
, _
FOR THE UfS'. NUCLEAR REGULATORY COMMISSION i
l
original signed by B. A. Riedlinger i
I
Date January 28, 1987 By ,
Beth A. Riedlinger g
Health Physicist (Licensing) i
Nuclear Materials Safety Section i
Region Y l
i
l
b
1
p
; ' ,, i
f
W
,
f
h
w..............--.... _ . ...--.....--...-. _ -- .,,.J
}}